ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will
present at the 14th Annual Needham Healthcare Conference on
Tuesday, April 14, 2015 at 3:00 p.m. The presentation will be web cast
and may be accessed through the investor relations section of the
Company’s website, http://investors.arqule.com/.
About ArQule
ArQule is a biotechnology company engaged in the research and
development of next-generation, small-molecule cancer therapeutics. The
Company’s targeted, broad-spectrum products and research programs are
focused on key biological processes that are central to human cancers.
ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is
tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor
tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to
inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase
inhibitor designed to preferentially inhibit the fibroblast growth
factor receptor (FGFR) family; and ARQ 761, a Beta lapachone analog
being evaluated as a promoter of NQ01-mediated programmed cancer cell
necrosis. ArQule’s current discovery efforts are focused on the
identification of novel kinase inhibitors, leveraging the Company’s
proprietary library of compounds.
Copyright Business Wire 2015